Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that decreases the amount of acid produced in the stomach. It is available for oral and intravenous administration.
## Primary Indications
* Gastroesophageal reflux disease (GERD) symptomatic treatment and maintenance therapy
* Erosive esophagitis healing and maintenance therapy
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
* Treatment of duodenal ulcers and gastric ulcers
* Adjunct therapy in *Helicobacter pylori* eradication
## Adult Dosing
* **GERD (Symptomatic treatment):** 20 mg orally once daily. May increase to 40 mg daily if needed.
* **GERD (Maintenance):** 20 mg orally once daily.
* **Erosive esophagitis (Healing):** 40 mg orally or IV once daily for 4 to 8 weeks.
* **Erosive esophagitis (Maintenance):** 20 mg orally once daily.
* **Duodenal Ulcers:** 40 mg orally once daily for 2 to 4 weeks.
* **Gastric Ulcers:** 40 mg orally once daily for 4 to 8 weeks.
* **Pathological hypersecretory conditions:** Starting dose 40 mg orally or IV twice daily. Doses may be increased to 240 mg daily, given as 40 mg every 6 hours.
* ***H. pylori* eradication (Triple therapy):** 40 mg orally twice daily for 7 to 14 days, in combination with clarithromycin and amoxicillin or metronidazole.
* **IV Administration:** Typically 40 mg IV once daily for patients unable to take oral medication.
## Pediatric Dosing
* **GERD (Symptomatic treatment):**
* **1 month to <5 years:** 20 mg orally once daily.
* **5 to <12 years:** 20 mg orally once daily. May increase to 40 mg daily.
* **≥12 years:** 40 mg orally once daily for healing erosive esophagitis, then 20 mg orally once daily for maintenance.
* **Erosive esophagitis (Healing):**
* **≥12 years:** 40 mg orally or IV once daily for 4 to 8 weeks.
* **Pathological hypersecretory conditions:**
* **≥12 years:** Dosing varies based on clinical response.
*Note: Pediatric dosing for IV formulations is less established and may depend on local protocols.*
## Dose Adjustments
No dose adjustment is generally required for hepatic impairment with oral pantoprazole at doses up to 40 mg daily. For IV administration or higher oral doses in moderate to severe hepatic impairment, a dose of 20 mg daily is recommended. No dose adjustment is necessary for renal impairment.
## Contraindications
* Known hypersensitivity to pantoprazole, other benzimidazoles, or any component of the formulation.
* Use of rilpivirine-containing products.
## Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, dizziness, flatulence.
Less Common/Serious: *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine) with prolonged use, hypomagnesemia, vitamin B12 deficiency, lupus erythematosus.
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** Antifungals (ketoconazole, itraconazole), certain tyrosine kinase inhibitors (e.g., erlotinib, gefitinib), certain antiretrovirals (e.g., rilpivirine, atazanavir). Pantoprazole can decrease absorption.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Monitor for potential interactions with drugs like clopidogrel and diazepam.
## Monitoring
* Assess for improvement of GERD symptoms.
* Monitor for signs of *C. difficile* infection.
* Consider magnesium levels with prolonged therapy, especially with diuretic use.
* Monitor for signs of bone fracture.
* Monitor for signs of vitamin B12 deficiency with long-term use.
## Clinical Pearls
* Administer oral pantoprazole at least 30 minutes before a meal.
* IV pantoprazole is a suspension that must be reconstituted and then further diluted prior to infusion.
* Long-term PPI use is associated with increased risk of fractures, *C. difficile* infection, and hypomagnesemia. Use the lowest effective dose for the shortest duration necessary.
* Discontinuation of PPIs should be considered gradually to avoid rebound acid hypersecretion.
---
**Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines for definitive patient management decisions.
